Extensive new data further confirms efficacy of budesonide/formoterol maintenance and reliever therapy in reducing exacerbations

New data presented at the European Respiratory Society (ERS) congress demonstrate the efficacy of budesonide/formoterol maintenance and reliever therapy (Symbicort SMART*) in reducing exacerbations and improving daily asthma control in patients with uncontrolled asthma. [click link for full article]

More: continued here

Filed under: Pharma Industry on September 21st, 2007